May 19, 2020 / 6:37 AM / 12 days ago

BRIEF-Lidds: Liproca Phase IIb Study Results Indicate Cancer Control

May 19 (Reuters) - Lidds AB:

* REG-LIPROCA PHASE IIB STUDY RESULTS INDICATE CANCER CONTROL

* STUDY MET BOTH PRIMARY AND SECONDARY ENDPOINTS

* MRI DATA SHOWS NO PROGRESSION OF PROSTATE CANCER IN ANY PATIENTS, AND EVEN REGRESSION IN SOME PATIENTS

* FINAL DATA FROM LPC-004 STUDY CONFIRMS LIPROCA® DEPOT’S POTENTIAL AS A SAFE AND EFFECTIVE ANTI-ANDROGEN TREATMENT FOR PROSTATE CANCER PATIENTS THAT CURRENTLY ARE NOT TREATED BUT KEPT UNDER ‘ACTIVE SURVEILLANCE’ Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below